Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab
Risk factors for relapse in AAV vary by treatment phase. Monitoring markers of inflammation and immune reconstitution may identify patients at risk for relapse, particularly after treatment withdrawal.
Authors
- Ulrich Specks (ORCID: https://orcid.org/0000-0002-6559-1206)
- Carol A. McAlear (ORCID: https://orcid.org/0000-0002-0016-6866)
- Rennie L. Rhee (ORCID: https://orcid.org/0000-0002-4907-0304)
- Ian Green
- Ellen Romich (ORCID: https://orcid.org/0000-0002-8233-4703)
- David R.W. Jayne (ORCID: https://orcid.org/0000-0002-1712-0637)
- Rona Smith (ORCID: https://orcid.org/0000-0002-7438-5156)
- Joshua F. Baker (ORCID: https://orcid.org/0000-0003-0170-028X)
- Peter A. Merkel (ORCID: https://orcid.org/0000-0001-9284-7345)
- Thomas R. Riley (ORCID: https://orcid.org/0009-0003-0194-7562)
Institutions
- Mayo Clinic (US)
- University of Cambridge (GB)
- Hospital of the University of Pennsylvania (US)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Cambridge School (PT)
- Bridge University (SS)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1002/art.70025
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Pennsylvania
- National Institute for Health and Care Research
- Ministry of Health, Labour and Welfare
- Versus Arthritis
- National Institutes of Health
- Genentech
- NIHR Cambridge Biomedical Research Centre
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Center for Research Resources
- National Center for Advancing Translational Sciences